BioNTech sees up to 17 billion eur in vaccine revenue this year
Reuters
Published Nov 09, 2021 06:47AM ET
Updated Nov 09, 2021 07:21AM ET
By Ludwig Burger
FRANKFURT (Reuters) - Germany's BioNTech SE (NASDAQ:BNTX) said the COVID-19 vaccine it is developing with partner Pfizer (NYSE:PFE) will likely generate up to 17 billion euros ($19.6 billion) in revenues this year, as booster shots take hold and use in children increases.
Based on planned deliveries of up to 2.5 billion doses so far, BioNTech said in a statement on Tuesday that it expects 16 billion to 17 billion euros in revenue accruing to it from the vaccine this year
That was up from a forecast in August of 15.9 billion euros based on deliveries plus an order backlog of about 2.2 billion doses at the time.
That figure includes milestone payments from partners and a share of gross profit in its partners' territories, the company added.
Pfizer, for its part, last week said it expected to book $36 billion in 2021 sales of the COVID-19 vaccine and forecast another $29 billion from the shot in 2022, topping analyst estimates for both years.
The company reiterated that no clinical data so far suggested the need for a new vaccine that addresses the highly contagious delta variant, or any other current variant, given the efficacy of two or three shots of its established product.
It is, however, working on new vaccine versions targeting the delta and alpha variants to establish a development and launch routine in case the need for adjusting to as-yet unknown variants arises in future.
Other vaccine makers, such as AstraZeneca (NASDAQ:AZN) and its partner Oxford University, have embraced a similar approach, in particular to respond quickly to any future mutation that enables the virus to evade established vaccines.
BioNTech and Pfizer "are establishing a preemptive prototype approach to evaluate the development, manufacturing and regulatory processes for variant specific vaccines," it said.
BioNTech reaffirmed statements by the partners that they expect to manufacture up to 3 billion doses by the end of 2021 and potentially up to 4 billion doses in 2022.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.